You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaNervous SystemProduct ClassPsychoanalepticsPharmacological SubgroupAnti-Dementia DrugsChemical SubgroupAnticholinesterasesCondition StudiedAlzheimer Disease
Sponsor Protocol NumberGALALZ3005Enrollment2051Data PartnerJohnson & Johnson% Female64.8%Mean/Median Age (Years)73.0% White99.9%
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
- 2024-0840 : Gender differences in the efficacy of anti-dementia medication in Alzheimer’s disease: a systematic review
- 2024-0456 : Development of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's disease
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2021-4743 : Machine Learning Approaches to Predicting Treatment Outcomes in Alzheimer's Disease
- 2021-4683 : The effects of systemic anti-infective concomitant medications on progression of neurological diseases
- 2020-4448 : Reanalysis of Alzheimer's Disease Clinical Trials Using Longitudinal Latent Trait Models
- 2020-4390 : A novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects
- 2020-4323 : Identification of biomarkers associated with Alzheimer's disease progression that correlate with responses to medications.
- 2020-4275 : Machine Learning Applications for Improving the Efficiency of Clinical Trials in Alzheimer's Disease
- 2019-3936 : Unbiased Treatment Efficacy Detection Methods with Patient Centered Outcomes
- 2017-1671 : Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and IPD NMA